Compare CMRE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | MPLT |
|---|---|---|
| Founded | 1974 | 2018 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2010 | 2025 |
| Metric | CMRE | MPLT |
|---|---|---|
| Price | $14.05 | $8.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $20.00 | ★ $26.54 |
| AVG Volume (30 Days) | ★ 347.2K | 343.7K |
| Earning Date | 11-03-2026 | 12-03-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.45 | $7.46 |
| 52 Week High | $18.06 | $40.43 |
| Indicator | CMRE | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 30.63 |
| Support Level | $13.86 | $7.46 |
| Resistance Level | $15.76 | $14.22 |
| Average True Range (ATR) | 0.45 | 0.58 |
| MACD | -0.10 | 0.12 |
| Stochastic Oscillator | 25.12 | 23.71 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.